Eastgate Biotech Corp. (ETBI)

Market Cap	105.79K -97.5%
Revenue (ttm)	137.64K +45,325.1%
Net Income	-3.82M
EPS	-0.01
Shares Out	1.06B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,000
Average Volume	1,362,180
Open	0.0001
Previous Close	0.0001
Day's Range	0.0001 - 0.0001
52-Week Range	0.0000 - 0.0045
Beta	-4,066.71
RSI	47.46
Earnings Date	n/a

About Eastgate Biotech

Eastgate Biotech Corp., a development stage company, develops novel formulations of natural compounds and pharmaceutical products. The company is developing pharmaceutical products, such as Lorazepam oral spray for acute seizures emergency treatment; Ketoconazole 2% topical ointment for treatment of skin fungal infections; and Metformin chewable/ sublingual tablets for treatment of type 2 diabetes. It is also developing natural products and dietary supplements, including E-drops Nano and PURALEN that are self-nanoemulsifying compositions contai...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 3
• Stock Exchange: OTCMKTS
• Ticker Symbol: ETBI